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Visceral leishmaniasis remains a public health problem worldwide. This illness was included by the World Health Organization
in the list of neglected tropical diseases targeted for elimination by 2015. The widespread emergence of resistance to pentavalent
antimonials in India where half cases occur globally and the unavailability of a vaccine in clinical use constitute major obstacles
in achieving this goal. The last decade new antileishmanials became available, including the oral agent miltefosine. However, in
poor endemic countries their wide use was curtailed because of the high costs, and also due to concerns of toxicity and emergence
of resistance. Various mechanisms of antileishmanial resistance were identiﬁed recently in ﬁeld isolates. Their elucidation will
boost the design of new drugs and the molecular surveillance of resistance. Combination regimens should be evaluated in large
trials. Overall, the development of antileishmanials has been generally slow; new drugs are needed. In order to control visceral
leishmaniasis worldwide, treatment advances should become aﬀordable in the poorest countries, where they are needed most.
1.Introduction
Visceral leishmaniasis (VL; also known as kala azar) is a
protozoan systemic infection, which is almost always fatal
if left untreated. This illness is endemic in several tropical
and subtropical regions and in the Mediterranean basin. The
estimated annual global burden of VL is 500000 new cases
and more than 50000 deaths, of which 90% occur just in ﬁve
countries—India, Bangladesh, Nepal, Sudan, and Brazil [1].
VL is transmitted through hematophagous sandﬂies and is
caused by Leishmania donovani in the Indian subcontinent,
Asia,andAfrica,L.infantumintheMediterraneanbasin,and
L. chagasi in South America. After an incubation period of
several months, typical VL manifests with intermittent fever,
weight loss, massive hepatosplenomegaly, and progressive
deterioration of the host; hemorrhages and edemas may
develop late in the course [2–4]. Leishmaniasis was selected
by the World Health Organization for elimination by 2015,
along with other neglected tropical diseases [5]. Since there
is no antileishmanial vaccine in clinical use, control of VL
relies almost exclusively on chemotherapy.
For almost seven decades pentavalent antimonials con-
stituted the standard antileishmanial treatment worldwide,
however the last 15 years their clinical value was jeop-
ardized due to the widespread emergence of resistance
to these agents in Bihar, India, where half of VL cases
occur globally [6] .T h el a s td e c a d en o v e lf o r m u l a t i o n so f
conventionalantileishmanialsaswellasnewdrugs,including
the oral agent miltefosine, became available or are under
investigation. In practice, however, their wide use in poor
countries is hampered mainly due to high costs and also
due to concerns of toxicity and emergence of resistance
[6]. In response to concerns about preserving the currently
available antileishmanials, especially in regions with anthro-
ponotic parasite transmission, there is growing interest on
combination regimens. Control of VL in poor countries is
further compromised by the emergence of human immun-
odeﬁciency virus (HIV)-VL-coinfection [7]. This article will
review recent publications on antileishmanial drugs, with
emphasis on resistance issues. Strategies to preserve the
activity of currently available drugs will be addressed.
2. Pathogenesis andImmune Response
Leishmanias are obligatory intracellular protozoan parasites.
Theparasitesremainwithintheirvectorsasextracellularpro-
mastigotes [8]. Following sandﬂy bite, neutrophils migrate2 Journal of Biomedicine and Biotechnology
locally and capture the parasites, however the latter have the
ability to escape and subsequently invade the macrophages
of the skin, where they diﬀerentiate and replicate as amastig-
otes [9, 10]. From there, parasites disseminate and invade
additional macrophages of the reticulo-endothelial system,
and ﬁnally inﬁltrate the bone marrow, liver, and spleen [8].
VL should be regarded as a state of long-term parasitism,
since leishmanias are not eradicated completely but rather
remaininskinmacrophagesforlifetime,evenaftersuccessful
treatment in hosts with intact T-cell immune responses. In
skin, leishmanias act as a reservoir for the potential relapse
of symptomatic VL. The risk for relapse increases when T-
cell immune responses are impaired and irrespectively of
prior antileishmanial treatment, as noted in HIV-infected
patients [7, 11, 12]. Relapses usually peak 6–12 months after
treatment.
Following Leishmania infection, host immune responses
are elicited. Immune responses are characterized by a
mixed T-helper cell-type 1 (Th1) and Th2 response, the
production of cytokines, and the activation of macrophages
[13–15]. High levels of speciﬁc antibodies are also detected
howevertheirexactroleremainsunclear[8].Recentevidence
indicates that the ﬁrst weeks following infection, neutrophils
play a signiﬁcant role in the killing of parasites and the
development of a protective Th1 immune response [9, 10].
The immunologic mechanisms that underlie the resolu-
tion of infection or the progression and systemic dissemina-
tion of leishmanias have not been elucidated completely so
far.Followinginfection,T-cell-dependentimmuneresponses
are elicited in an integrated fashion. Interleukin 12 (IL12)
promotes cell-mediated immunity. Activated CD4 T cells
are recruited to cutaneous or visceral sites of infection
and direct the local inﬂammatory responses. CD4 T-cell
responsesareassociatedwiththeinterferon(IFN)-γ-induced
macrophage activation through participation of cytokines,
mainly IL12 and also IL2 and tumor necrosis factor, and the
intracellular parasite killing by activated macrophages [8].
IL4 also plays an important role in eﬀective antileishmanial
chemotherapy, which appears to be modulated by IFN-γ-
production [16]. Deactivation of macrophages, suppression
of Th1 responses, and dissemination of leishmanial infection
are induced by IL10 [14]. Increased IL10 levels have been
detected repeatedly in human VL and are considered crucial
in uncontrolled leishmanial infection [13, 14]. Targeting
IL10 has been associated with activation of Th1 responses
and parasite killing, whereas IL10 suppression constituted a
critical step in vaccine-mediated immunotherapy [17]. Most
data on cellular immune responses and cytokines have been
observed in murine models; similar results have been found
in humans.
3. Antimonials
Although pentavalent antimonials (meglumine antimoniate
and sodium stibogluconate) are in clinical use for several
decades, there are aspects on their mechanism of action
that remain unclear. It is generally accepted that pentava-
lent antimonials (SbV) are the prodrug, and that they
should convert to trivalent antimonials (SbIII) in order to
demonstrate their antileishmanial activity [18–20]. Recent
evidence indicates that antimonials kill leishmanias by a
processofapoptosis[20].Thiolmetabolismiscriticalintheir
mechanism of action. Trypanothione is the major thiol in
leishmanias. SbIII inhibits trypanothione reductase in vitro,
inducingthelossofintracellularthiolsandalethalimbalance
in thiol homeostasis, leading to accumulation of reactive
oxygen species [20–22]. In order for antimonials to exert
their action, an almost intact immune system of the host is
required.
Initially antimonials were given at 10mg/kg for 6–10
days with >90% cure rates, however after the ﬁrst treatment
failures occurred in India two decades ago, higher doses
and prolonged schemes (up to 20mg/kg for 30 days) were
introduced gradually and in parallel with the increasing
rates of antimony unresponsiveness [23]. However, the dose
escalation policy did not prevent further emergence of
resistance, but rather selected resistant parasites. During the
last decade, antimonial resistance and therapeutic failures
reached epidemic dimensions in Bihar, India; nowadays, up
to 60% of newly diagnosed VL cases in this area do not
respond to antimonials [23]. Inadequate treatment in terms
of dosing and duration, and poor compliance promote the
widespread antimonial resistance in India. In this country,
the high incidence rate of unresponsiveness to antimonials
is further sustained by the anthroponotic transmission of
leishmanial infection, which increases the chances for the
rapid spread of resistant parasites among humans once they
emerge [24, 25]. Low rates of antimonial resistance have
been reported in Sudan also [26]. Pentavalent antimonials
were abandoned in India, however they remain the ﬁrst
treatment choice in most VL-endemic areas in the rest
of the world, with eﬃcacy rates exceeding 90%–95% and
low case fatality and relapse rates [2–4, 27]. Low cost is
their main advantage. Disadvantages include intramuscular
administration, prolonged treatment, and transient, but
occasionally life-threatening adverse eﬀects, such as cardiac
arrhythmias, increased hepatic transaminases, pancreatitis,
and pneumonitis [2–4, 23].
While several experimental studies on antimonial resis-
tance have been conducted with parasite mutants selected in
vitro using step-wise increasing drug concentrations, resis-
tance mechanisms in ﬁeld parasites have not been elucidated
in details. Mechanisms of in vitro antimonial resistance
may diﬀer from mechanisms in ﬁeld isolates [28]. Similarly,
in vitro unresponsiveness does not necessarily translate to
clinical resistance [29]. Reduction of drug concentration
within the parasite, either by decreasing drug uptake or by
increasing eﬄux/sequestration of the drug, constitutes the
primarymechanismofantimonialresistance;otherpotential
resistance mechanisms include inhibition of drug activation,
inactivation of active drug, and gene ampliﬁcation [18, 20,
28, 30–32].
Thiol metabolism possesses a key role in both clinical
and laboratory-generated resistance mechanisms. It has been
found that elevated intracellular thiol levels and overexpres-
sion of tryparedoxin peroxidase are associated with high
levelsofSbIIIresistance[22,31,33].However,itappearsthatJournal of Biomedicine and Biotechnology 3
more than one step in thiol metabolism should be impaired
in order for resistance to emerge, indicating that antimonial
resistance is multifactorial. In natural antimonial resistance,
the impaired thiol metabolism results in inhibition of SbV
activation and decreased uptake of the active form SbIII
by amastigotes; these processes are accomplished by the
lower expression of the genes γ-glutamylcysteine synthetase,
ornithine decarboxylase, and aquaglyceroporin 1, which are
involved in the metabolisms of glutathione and trypathione,
and uptake of SbIII, respectively [18, 19, 28]. It has been
suggested that decreasing the intracellular thiol concentra-
tionsthroughthioldepletorsmayincreasetheleishmanicidal
action of drugs and thus reverse parasite resistance [33].
Overexpression of the membrane-bound ATP-binding
cassette (ABC) transporters on the surfaces of leishmanias
is another mechanism of antimonial resistance. In addition
to leishmanias, this transport system modulates the eﬄux
and intracellular accumulation of various drugs and thus
resistance in other parasites (e.g., Plasmodium spp.) and also
in cancer cells. Overexpression of ABC transporters concerns
laboratory-derived and in-ﬁeld resistant parasites [31, 34]. It
hasbeenfoundthat,incontrasttoinfectionwithSb-sensitive
L. donovani isolates, infection with Sb-resistant L. donovani
isolates upregulates the multidrug resistance-associated pro-
tein 1 (MRP1) and the permeability glycoprotein (P-gp) in
host cells, thus inhibiting intracellular drug accumulation by
decreasing antimony inﬂux [31, 34, 35]. In animal models,
inhibition of the proteins MRP1 and P-gp by lovastatin
reverses their action on drug accumulation, and allows them
to escape a fatal outcome [35]. These results indicate that
lovastatin, which can inhibit P-gp and MRP1, might be
beneﬁcial for reverting Sb resistance in VL [35]. Flavonoid
dimers are also known to reverse antimonial resistance in
leishmanias in vitro by inhibiting ABC transporters and
increasing the intracellular accumulation of the drug [36].
These ﬁndings should be conﬁrmed in animal models.
In conclusion, the overall phenomenon of antimonial
resistance is multifactorial. Several mechanisms of resistance
toantimonialshavebeendetectedamongclinicalleishmanial
isolates. However, the modes of emergence and spread of
antimonial resistance in ﬁeld remain largely unknown. A
monoclonal or oligoclonal distribution of resistant parasites
would be expected, given the anthroponotic nature of leish-
manial transmission in the Indian subcontinent. However,
a study of 13 Sb-resistant and 11 Sb-sensitive L. donovani
clinical isolates collected from Nepal using DNA ﬁngerprint-
ing methods in a population genetics approach revealed a
polyclonal distribution of resistant isolates and three major
clusters, each containing both sensitive and resistant isolates
[37]. Analysis of isolates of paired samples collected from the
same patients before treatment and after treatment failure
showed primary as well as acquired resistance [37]. Based
on these ﬁndings, the hypothesis of independent events of
emergence of drug resistance appears likely, which suggests
a pleiotropic answer of leishmanias to drug pressure, as
indicated by the various existing mechanisms of antimonial
resistance. High genomic variability among L. donovani
clinical isolates from India was also found with the use of
ampliﬁed fragment length polymorphism, suggesting that
various point genetic rearrangements provide the frame for
the transition of a parasite from sensitive to resistant [38].
4. Amphotericin-B and Its Lipid Formulations
Conventional amphotericin B has been used as a second-
line treatment for VL since the 1960s. This drug exhibits
an excellent antileishmanial activity with >90%–95% cure
rates in Indian VL cases. Unresponsiveness and relapses
occur rarely, except among HIV-infected patients [3, 11, 12].
In this population, secondary episodes of VL are common
and are attributed mainly to relapse but also to reinfection
[11]. A recent study failed to disclose decreased susceptibility
among leishmanias collected from HIV-infected patients
during repeated VL episodes (mean follow-up period: 35.6
months; range: 3–137 months), despite repeated courses of
amphotericin B; these data indicate that amphotericin B will
remain a very useful drug for the treatment or secondary
prophylaxis in this group of patients, even after repeated use
[11].
The routine scheme of conventional amhotericin B
is 1/mg/kg administered on alternate days for a total of
30 days, however, a recent study in India showed 96%
cure rates with a dose of 0.75mg/kg/day for 15 days [6].
Major disadvantages of conventional amphotericin B are its
prolonged administration and the frequent adverse eﬀects,
such as infusion-related fever and chills, nephrotoxicity, and
hypokalemia, which necessitate administration in hospital
[6].ConventionalamphotericinBisusedextensivelyinIndia
for cases unresponsive to antimonials or even as a ﬁrst line
drug. However, outside India this drug does not oﬀer any
advantage over pentavalent antimonials.
Lipid formulations of amphotericin B improved highly
the safety proﬁle of this drug. Lipid formulations are taken
selectively by the reticulo-endothelial system, and exhibit
a highly localized enhanced antileishmanial action. There
are three lipid formulations of amphotericin B: liposo-
mal amphotericin B, amphotericin B lipid complex, and
amphotericin B cholesterol dispersion. Currently, liposomal
formulationsofamphotericinBaretheﬁrsttreatmentchoice
in southern Europe endemic countries as well as in other
developed countries, because of their rapid and up to 100%
cure rates with 3–5 days schemes, improved convenience for
the patient, and reduction of health-care costs [27, 39, 40].
However, in poor countries even short courses of liposomal
formulations are unaﬀordable, and the selection of antileish-
manial treatment turns more to a question of cost than of
eﬃcacy or toxicity [6, 27]. The use of nanoparticles and
microspheres for the delivery of conventional amphotericin
B also increased its eﬃcacy against experimental VL [41–
43].Similarresultshavebeenreportedwiththeheat-induced
reformulation of amphotericin B [44].
5. Miltefosine
Miltefosine (hexadecylphosphocholine) is the ﬁrst orally
administered drug for VL and the latest to enter the
market. This agent is associated with high eﬃcacy rates,4 Journal of Biomedicine and Biotechnology
including cases unresponsive to antimonials [45, 46]. In
a phase IV multicenter trial in India of 1132 adults and
children with VL treated with miltefosine, cure rates were
82% per intention-to-treat analysis and 95% per protocol
analysis [47]. In this study, 3% of patients developed adverse
eﬀects,mainlygastrointenstinaltoxicity,andelevatedhepatic
transaminases and creatinine [47]. So far, miltefosine is
licenced in India, Germany, and Colombia. The scheme of
miltefosine is 100mg/kg/day for 28 days in adults weighing
≥50kg, 50mg/kg/day in adults <50kg, and 2.5mg/kg/day in
children (maximum dose: 100mg/day). Major concerns for
the wide use of miltefosine include its teratogenic potential
and its long half-life (approximately 150 hours) which may
facilitate the emergence of resistance. Miltefosine is strictly
forbidden in women of child-bearing age who may become
pregnant up to two months following drug discontinuation.
In India miltefosine is available over the counter, a fact that
may expose this drug to misuse and emergence of resistance.
Once generated, resistant parasites could spread rapidly,
endangering the life span of miltefosine in a country where it
is needed most.
The exact antileishmanial mechanism of miltefosine
remains largely unknown. The intracellular accumulation
of the drug appears to be the critical step for its action.
The intracellular accumulation of miltefocine includes the
following steps: binding to plasma membrane, internal-
ization in the parasite cell (two proteins, the miltefosine
transporter LdMT and its beta subunit LdRos3, are the most
signiﬁcant), and intracellular targeting and metabolism [48].
It has been found that miltefosine induces an apoptosis-
like cell death in L. donovani, by producing numerous
defects [48]. Miltefosine also induces several immunologic
and inﬂammatory eﬀects on macrophages. In animal mod-
els, miltefosine does not require T-cell-dependent immune
mechanisms in order to act, indicating that this agent can
be used in T-cell-deﬁcient patients [12, 48]. Recently, it was
found that miltefosine enhanced IFN-γ receptors and thus
IFN-γ responsiveness in L. donovani-infected macrophages;
in the same model, miltefosine induced an IL-12-dependent
Th1 response and reversed the Th2 response to Th1 response
[49].
Resistance to miltefosine may emerge easily during
treatment due to single point mutations [50, 51]. Decrease
in drug accumulation is the common denominator in all
miltefosine resistant Leishmania lines studied to date, and
this could be achieved through decreased uptake, increased
eﬄux, faster metabolism, or altered plasma membrane
permeability; the ﬁrst two mechanisms have been already
described in models of experimental miltefosine resistance
[48, 50]. Two proteins, miltefosine transporter LdMT and its
speciﬁc beta subunit LdRos3, form part of the miltefosine
translocation machinery at the parasite plasma membrane,
and are required for miltefosine uptake [48]. Experimental
mutations at LdMT or LdRos3 rendered the parasites
remarkably less sensitive to miltefosine, and this resistance
persisted in vivo; cross-resistance with other antileishma-
nials was not detected [48, 50]. The overexpression of ABC
transporters is another mechanism for acquisition of milte-
fosine resistance, through reduction of the drug intracellular
accumulation [48, 52]. Recently, a novel ﬂavonoid derivative
was designed and it was shown that the use of suboptimal
doses in order to overcome the overexpression of LtrMDR1
(a P-glucoprotein-like transporter belonging to the ATP-
binding cassette superfamily) was associated with a four-
fold increase of intracellular miltefosine accumulation in the
resistant Leishmania lines [53]. Furthermore, modiﬁcations
in lipid compositions of membranes and sterol biosynthesis
have been detected in miltefosine-resistant L. donovani pro-
mastigotes [54]. Since membrane ﬂuidity and permeability
are inﬂuenced by lipid composition, their modiﬁcation may
aﬀect drug-membrane interactions [54]. A case of a healthy
patient with VL who relapsed 10 months after successful
treatment with miltefosine for 28 days was reported recently
[55].
6. Paromomycin
Paromomycin (aminosidine) is an aminoglycoside with
antileishmanial activity. In a phase III study of VL in
India, this drug was associated with 94.6% cure rates,
similar to amphotericin B [56]. Adverse eﬀects were more
frequent in the paromomycin-treated group compared with
the amphotericin B-treated group (6% versus 2%, resp.);
paromomycin-related adverse eﬀects included elevated hep-
atic transaminases, ototoxicity, and pain at injection-site
[56]. Currently, paromomycin is under phase IV clinical
trials. Paromomycin is inexpensive but requires daily intra-
muscular injections for 21 days [6].
Paromomycin inhibits protein synthesis and modiﬁes
membrane ﬂuidity and permeability. An in vitro study
showed that following a 72-hour exposure to L. dono-
vani promastigotes and amastigotes to paromomycin, the
mitochondrial potential was decreased, which indicates that
mitochondria are the targets of the drug [57]. In laboratory-
derived resistant parasites developed through serial-passage
increasing-drug concentrations, paramomycin uptake was
decreased compared to the wild-type parasite, in association
with inhibition of protein synthesis; no cross-resistance with
other antimonial agents was detected [57]. Since paro-
momycin is an aminoglycoside, it is possible that resistance
will emerge rapidly if used as monotherapy.
7. Combination Regimens
The rational for using combination regimens with diﬀerent
resistance mechanisms over monotherapy relies on the
expected enhanced eﬃcacy (through synergy or additive
activity without drug interaction), shorter treatment dura-
tion, less toxicity, improved compliance, reduced likelihood
ofemergenceofresistance,andreducedcosts.Acombination
policy for VL is supported by the fact that antileishmanial
drugs belong to diﬀerent chemical classes. Recent studies
have investigated this option. In a retrospective study con-
ducted among Sudanese patients with VL, it was found that
combination of sodium stibogluconate and paromomycin
administered for 17 days was associated with higher cure
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monotherapy administered for 30 days (44%–86% lower
odds of death in the combination group) [58]. Combina-
tions of miltefosine with amphotericin B, paromomycin or
pentavalent antimonials have been evaluated in an in vivo
model and revealed that the combinations of miltefosine
with amphotericin B or paromomycin were eﬃcacious [59].
These preliminary data justiﬁed a recent study in Bihar,
India, comparing 5mg/kg of liposomal amphotericin B
administered once (group A; 45 patients), 5mg/kg of lipo-
somal amphotericin B administered once plus miltefosine
for either 10 days (group B; 46 patients) or 14 days (group
C; 45 patients), 3.75mg/kg of liposomal amphotericin B
administered once plus miltefosine for 14 days (group D;
45 patients), and 5mg/kg of liposomal amphotericin B
administered once followed by miltefosine for 7 days (group
E; 45 patients); in this study, similar ﬁnal cure rates (91%–
98%) were noted in all treatment groups [60]. These data
indicate that a single dose of liposomal amphotericin B
followed by 7–14 days of miltefosine is active against Indian
VL [60]. In this study, all patients were treated in an
outpatient setting. Large, randomized-controlled trials are
required before adaptation of combination regimens.
Several combination regimens with investigational
agents have been tested in vitro and in animal models [61].
The plant-derived immunostimulant agent picroliv has
no antileishmanial activity, however when administered
with half-dose miltefosine increases signiﬁcantly the
activity of the later [62]. The combination of verapamil
(a calcium channel blocker) and diperoxovanadate (a
potent antileishmanial agent) with sodium antimony
gluconate reversed the in vitro antimonial resistance among
clinical L. donovani isolates [63, 64]. Diperoxovanadate also
demonstrated immunomodulating eﬀects by increasing
IFN and decreasing IL-10 [64]. These combinations deserve
further testing in VL cases unresponsive to antimonials.
8. Strategies to Preserve the Efﬁcacy of
CurrentlyAvailable Antileishmanials
In addition to intrinsic pharmacologic features, there is a
number of human parameters that may favor the emergence
and spread of leishmanial resistance. These include poor
compliance, expensive treatment, availability of antileishma-
nial drugs over the counter, and limited access to health-
care facilities for early diagnosis and treatment. Given the
current situation of the widespread emergence of antimonial
resistance in India, there is growing concern to preserve the
eﬃcacy of novel antileishmanials. Such a strategy should
focus on the following axons.
(1) Treatment of VL should be based on guidelines
for prompt diagnosis, selection of ﬁrst-line drugs,
management of cases unresponsive to antimonials,
and HIV-coinfected cases. A recent study of Indian
VL cases revealed that a strategy of treatment with
antimonials (ﬁrst choice) or amphotericin B (second
choice), based on culture and susceptibility results,
compared with an empiric treatment strategy, was
associated with higher cure rates (86.21% versus
35.71%), and reduced expenses, duration of hospi-
talization, and likely period of spread of parasites in
the community [65].
(2) In order to enhance compliance, directly observed
therapy for antileishmanials should be implemented,
like in tuberculosis control programs.
(3) VL cases should be treated early in order to avoid




(5) Antileishmanial treatment should be provided free-
of-charge through the health-care system.
(6) The emergence and spread of antileishmanial resis-
tance should be monitored.
(7) The eﬃcacy and safety of combination regimens
should be evaluated in large trials.
9. Conclusions
The control of VL globally is challenged by the widespread
emergence of antimonial resistance in India. The last decade
new formulations of conventional antileishmanial drugs as
well as new agents became available. The wide use of the
oral agent miltefosine was hampered by the potential for
teratogenicity and emergence of resistance. Combination
regimens should be evaluated in large trials. The last years
several mechanisms of in ﬁeld antileishmanial resistance
were identiﬁed. Understanding their molecular and bio-
chemical characteristics will lead the design of new drugs
and also the molecular surveillance of resistance. In order
not to jeopardize the life span of available antileishmanials,
their delivery, clinical response, and resistance should be
monitored. Overall the development of antileishmanials has
been generally slow; new drugs are needed.
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